MedTrace Logo

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

NCT06345183 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 327

Last updated 2025-11-06

No results posted yet for this study

Summary

This observational study aims to describe demographic, clinical characteristics, treatment patterns outcomes of participants with advanced Renal Cell Carcinoma (aRCC) receiving either Nivolumab + Ipilimumab, or Pembrolizumab + Lenvatinib combination therapy

Conditions

  • Advanced Renal Cell Carcinoma (aRCC)

Interventions

COMBINATION_PRODUCT

Nivolumab + Ipilimumab combination therapy

As per product label

COMBINATION_PRODUCT

Pembrolizumab + Lenvatinib combination therapy

As per product label

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-19
Primary Completion
2024-04-04
Completion
2024-04-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06345183 on ClinicalTrials.gov